Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Plus Therapeutics ( (PSTV) ).
Plus Therapeutics has implemented a 1-for-25 reverse stock split of its common stock, converting every 25 issued and outstanding shares into one share without changing the $0.001 par value or stockholder voting rights. The move, approved by stockholders on August 7, 2025 and executed via a charter amendment filed on April 1, 2026, reduced outstanding shares from about 171.6 million to about 6.9 million and became effective at 12:01 a.m. Eastern time on April 2, 2026, when post-split trading on the Nasdaq Capital Market under the ticker PSTV commenced.
The reverse split, which leaves authorized shares unchanged and thus increases the pool available for future issuance, is designed to boost the per-share trading price to help the company meet Nasdaq’s $1.00 minimum bid requirement and maintain its listing. Fractional shares will not be issued, with holders instead receiving cash in lieu, and all equity awards and warrants are being proportionally adjusted, resulting in a uniform impact on ownership percentages aside from minor changes related to fractional share treatment.
The most recent analyst rating on (PSTV) stock is a Sell with a $0.15 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.
The score is driven primarily by very weak financial performance (zero 2025 revenue, widening losses, and accelerating cash burn), reinforced by bearish technicals with the stock far below key moving averages. Positive corporate updates and governance additions help at the margin, but do not outweigh the current funding and profitability risks; valuation signals are limited by negative earnings.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc. is a Houston-based clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Its pipeline combines image-guided local beta radiation with targeted drug delivery, with lead programs in leptomeningeal metastases and recurrent glioblastoma, supported by strategic manufacturing and supply-chain partnerships.
The company aims to leverage these advanced platform technologies to improve outcomes in indications with limited treatment options, positioning itself within the niche but growing market for radiopharmaceutical oncology therapies. Its partnerships are intended to support future potential commercialization of its product candidates across key neuro-oncology segments.
Average Trading Volume: 405,777
Technical Sentiment Signal: Sell
Current Market Cap: $26.73M
See more data about PSTV stock on TipRanks’ Stock Analysis page.